Compare Asana Inc. (ASAN) vs Enveric Biosciences Inc (ENVB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Asana Inc. vs Enveric Biosciences Inc — how do they compare? Asana Inc. trades at $9.25 (market cap $2.13B), while Enveric Biosciences Inc trades at $1.45 (market cap $6.20M). The key difference: Asana Inc. is far larger — about 343.5× Enveric Biosciences Inc's market cap, and Asana Inc. is trading nearer its 52-week high, Enveric Biosciences Inc nearer its low. Which is the better fit depends on your goals.
| ASAN | ENVB | |
|---|---|---|
Market Cap | $2.13B | $6.20M |
Sector | Consumer Cyclical | Health |
52-Week High | $15.19 | $17.40 |
52-Week Low | $5.46 | $1.27 |
Enterprise Value | $1.95B | $1.30M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Asana (ASAN) trades at $9.26, up 6.68% today, with a bullish technical signal from moving averages and a consensus price target of $10.33. Recent quarterly earnings have consistently beaten expectations, including Q1 2027 EPS of $0.10 versus $0.08 expected. Revenue growth is steady, reaching $724 million in 2025, but profitability remains negative with a net margin of -20.21%. The company is advancing its AI capabilities, highlighted by the StackAI acquisition announced on May 28, 2026.
The outlook is mixed: strong revenue growth and AI innovation support upside potential, but persistent losses and intense competition from Microsoft and Alphabet pose significant risks. Analyst sentiment is divided, with 42% buy ratings. Earnings momentum is key for sustained gains.
ENVB trades at $1.55, down 0.64% with a bullish technical signal despite negative profitability. The company shows promising clinical progress with its lead candidate EB-003, supported by recent FDA guidance and positive preclinical data. While quarterly earnings consistently beat expectations, the company remains unprofitable with negative ROE and ROA. Analyst sentiment is positive with 75% buy ratings.
Investment outlook hinges on successful drug development milestones, with regulatory progress and intellectual property expansion providing catalysts. Key risks include clinical trial outcomes, cash burn from operations, and dependence on financing activities. The stock presents speculative growth potential for risk-tolerant investors focused on biotech innovation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Asana Inc.
Asana Inc is a software company. The company provides a platform for work management that helps teams orchestrate work, from daily tasks to cross-functional strategic initiatives. It helps plan marketing campaigns, streamlines processes, manages sales, and manage product launches. Also, the company provides project management and workflow management solutions.
Read more on ASAN →About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →
